Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | SELE | P16581 | 1/20 | 0.32 |
| ▸ | GCK | P35557 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21802182 | 0.90 | MEN1 (0.43) | MEN1KMT2ACREBBPEP300POLB | |
| SCHEMBL29601953 | 0.87 | TSHR (0.37) | MEN1KMT2ACREBBPEP300MAPT | |
| SCHEMBL19635898 | 0.87 | TSHR (0.37) | MEN1KMT2ACREBBPEP300MAPT | |
| SCHEMBL19635178 | 0.81 | MEN1 (0.31) | MEN1KMT2ARAB9A | |
| SCHEMBL19635445 | 0.77 | MEN1 (0.38) | MEN1KMT2ACREBBPL3MBTL1RAB9A | |
| SCHEMBL29602501 | 0.77 | MEN1 (0.38) | MEN1KMT2ACREBBPL3MBTL1RAB9A | |
| SCHEMBL20521691 | 0.76 | NPC1 (0.32) | MEN1KMT2ARAB9AGCK | |
| SCHEMBL22437573 | 0.72 | KDM4C (0.34) | MEN1KMT2AL3MBTL1RAB9A | |
| SCHEMBL19253491 | 0.72 | KDM4C (0.34) | MEN1KMT2ACREBBPEP300L3MBTL1 | |
| SCHEMBL19615379 | 0.71 | KDM4C (0.39) | MEN1KMT2AL3MBTL1RAB9AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458459-B1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AG (DE) | 2022-04-27 | — | — | EP | disclosed |
| US-10981932-B2 | Macrocyclic indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-20 | — | — | US | disclosed |
| US-20200087322-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981932-B2 | Macrocyclic indole derivatives | CCND2, IDO1, CCNT2 | MEN1 114/4885KMT2A 772/4885CREBBP 1570/4885 |
| US-20200087322-A1 | MACROCYCLIC INDOLE DERIVATIVES | CCND2, CCNA1, CCNT2 | MEN1 140/4885KMT2A 897/4885CREBBP 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.